Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CSK | P41240 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21683247 | 1.00 | LNPEP (0.42) | LNPEPERAP2GRB2EPHX2NR1H4 | |
| SCHEMBL23943305 | 0.86 | GRB2 (0.41) | LNPEPERAP2GRB2EPHX2CSK | |
| SCHEMBL21683250 | 0.80 | CTSS (0.50) | — | |
| SCHEMBL21683249 | 0.80 | CTSS (0.50) | — | |
| SCHEMBL18067861 | 0.77 | ALDH1A1 (0.49) | LNPEPERAP2TPH1ERAP1PARP10 | |
| SCHEMBL30014801 | 0.73 | PPID (0.46) | HDAC6PARP10 | |
| SCHEMBL29531634 | 0.72 | SLC7A5 (0.57) | LNPEPERAP2 | |
| SCHEMBL8098048 | 0.72 | GRB2 (0.38) | GRB2ALDH1A1 | |
| SCHEMBL20951916 | 0.71 | GAA (0.41) | GRB2CSK | |
| SCHEMBL20950945 | 0.71 | CYP1A2 (0.40) | GRB2CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2020033317-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | LNPEP 1859/4885ERAP2 179/4885GRB2 993/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | LNPEP 1859/4885ERAP2 179/4885GRB2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.